Defining conversion therapy for esophageal squamous cell carcinoma

Satoru Matsuda; Takahiro Tsushima; Ken Kato; Chih-Hung Hsu; Jang Ming Lee; Ian Yu-Hong Wong; Hu-Lin Christina Wang; Chang Hyun Kang; Xufeng Guo; Shun Yamamoto; Takayuki Tsuji; Hirofumi Kawakubo; Hiroya Takeuchi; Simon Law; Yuko Kitagawa

doi:10.1002/ags3.12623

Defining conversion therapy for esophageal squamous cell carcinoma

Ann Gastroenterol Surg. 2022 Oct 19;7(1):7-9. doi: 10.1002/ags3.12623. eCollection 2023 Jan.

Authors

Affiliations

¹ Deepartment of Surgery Keio University School of Medicine Tokyo Japan.
² Division of Gastrointestinal Oncology Shizuoka Cancer Center Shizuoka Japan.
³ Department of Head and Neck, Esophageal Medical Oncology National Cancer Center Hospital Tokyo Japan.
⁴ Division of Medical Oncology, Department of Oncology National Taiwan University Hospital Taipei Taiwan.
⁵ Department of Surgery National Taiwan University Hospital Taipei Taiwan.
⁶ Department of Surgery, School of Clinical Medicine The University of Hong Kong Hong Kong China.
⁷ Division of Traumatology Far Eastern Memorial Hospital Taipei Taiwan.
⁸ Department of Thoracic and Cardiovascular Surgery Seoul National University Hospital Seoul Korea.
⁹ Department of Thoracic Surgery, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China.
¹⁰ Department of Surgery Hamamatsu University School of Medicine Hamamatsu Japan.

Abstract

A multimodality treatment conference with experts from across East Asia was held to establish a consensus for conversion therapy. An agreement was reached that conversion therapy was defined as surgery or chemoradiotherapy (CRT) aiming at cure after initial treatment for tumors that were initially unresectable due to adjacent organ invasion or distant metastasis.

Keywords: conversion surgery; conversion therapy; esophageal squamous cell carcinoma.

Publication types

Editorial